These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 31434613)

  • 1. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.
    Bianchi A; Lopez S; Altwerger G; Bellone S; Bonazzoli E; Zammataro L; Manzano A; Manara P; Perrone E; Zeybek B; Han C; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Newberg JY; Pavlick DC; Elvin J; Frampton GM; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Oct; 155(1):144-150. PubMed ID: 31434613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
    Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
    Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
    Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.
    Prasad CB; Prasad SB; Yadav SS; Pandey LK; Singh S; Pradhan S; Narayan G
    Sci Rep; 2017 Oct; 7(1):12876. PubMed ID: 28993682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
    Kwon M; Jang H; Kim EH; Roh JL
    Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
    Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
    Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
    van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1659-1670. PubMed ID: 32279088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitor re‑sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis.
    Wu J; Xiao S; Yuan M; Li Q; Xiao G; Wu W; Ouyang Y; Huang L; Yao C
    Mol Med Rep; 2019 Jan; 19(1):75-84. PubMed ID: 30431088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
    Han C; McNamara B; Bellone S; Harold J; Manara P; Hartwich TMP; Mutlu L; Yang-Hartwich Y; Zipponi M; Demirkiran C; Verzosa MSZ; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Dottino PR; Schwartz PE; Santin AD
    Gynecol Oncol; 2023 Mar; 170():172-178. PubMed ID: 36706643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.
    Norris RE; Adamson PC; Nguyen VT; Fox E
    Pediatr Blood Cancer; 2014 Jan; 61(1):145-50. PubMed ID: 24038812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
    Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
    Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
    Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.
    Arena S; Corti G; Durinikova E; Montone M; Reilly NM; Russo M; Lorenzato A; Arcella P; Lazzari L; Rospo G; Pagani M; Cancelliere C; Negrino C; Isella C; Bartolini A; Cassingena A; Amatu A; Mauri G; Sartore-Bianchi A; Mittica G; Medico E; Marsoni S; Linnebacher M; Abrignani S; Siena S; Di Nicolantonio F; Bardelli A
    Clin Cancer Res; 2020 Mar; 26(6):1372-1384. PubMed ID: 31831554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
    Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
    Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.